- Home
- BIIB vs MKC Comparison
BIIB vs MKC Comparison
Compare BIIB & MKC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- MKC
- Stock Information
- Founded
- BIIB 1978
- MKC 1889
- Country
- BIIB United States
- MKC United States
- Employees
- BIIB N/A
- MKC N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- MKC Packaged Foods
- Sector
- BIIB Health Care
- MKC Consumer Staples
- Exchange
- BIIB Nasdaq
- MKC Nasdaq
- Market Cap
- BIIB 25.1B
- MKC 20.1B
- IPO Year
- BIIB 1991
- MKC N/A
- Fundamental
- Price
- BIIB $160.85
- MKC $77.98
- Analyst Decision
- BIIB Buy
- MKC Hold
- Analyst Count
- BIIB 25
- MKC 9
- Target Price
- BIIB $258.57
- MKC $78.50
- AVG Volume (30 Days)
- BIIB 1.7M
- MKC 1.7M
- Earning Date
- BIIB 10-30-2024
- MKC 01-23-2025
- Dividend Yield
- BIIB N/A
- MKC 2.15%
- EPS Growth
- BIIB 10.05
- MKC 22.50
- EPS
- BIIB 11.06
- MKC 2.94
- Revenue
- BIIB $9,607,500,000.00
- MKC $6,678,500,000.00
- Revenue This Year
- BIIB N/A
- MKC $1.53
- Revenue Next Year
- BIIB N/A
- MKC $2.71
- P/E Ratio
- BIIB $14.54
- MKC $26.53
- Revenue Growth
- BIIB N/A
- MKC 1.11
- 52 Week Low
- BIIB $153.62
- MKC $63.88
- 52 Week High
- BIIB $268.30
- MKC $85.49
- Technical
- Relative Strength Index (RSI)
- BIIB 37.71
- MKC 51.87
- Support Level
- BIIB $158.44
- MKC $77.35
- Resistance Level
- BIIB $165.29
- MKC $78.82
- Average True Range (ATR)
- BIIB 4.09
- MKC 1.35
- MACD
- BIIB 1.04
- MKC 0.37
- Stochastic Oscillator
- BIIB 32.51
- MKC 86.69
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About MKC McCormick & Company Incorporated
In its 135-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers. And its reach is extensive, with nearly 40% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and Cholula, among others.